Search results for " trends" in Articles / App Notes

Article Expanding the Emerging Therapeutic Horizon
Despite the successes that have already been achieved with emerging therapy development and manufacturing, companies are still facing numerous challenges. Aspects such as demand for accelerate…

Article How to program, run and evaluate a design of experiments (DoE)
In this free, interactive course, Dr. Martin Sichting, Product Manager Lab Scale Chromatography Systems at Cytiva, guides you through the DoE process. You’ll learn how to program, run, and e…

Article Digital transformation of biopharmaceutical process development
Digital transformation has become an increasingly important topic for the biopharmaceutical industry as it leads to new opportunities for additional value creation and competitiv…

Article Improving Productivity During Process Development and Scaling of Your Process
PD Click here to view more Industry Leader Q&As >> Andreas Castan, PhD, Strategic Technology Partnerships Leader of Business Development & Strategy at Cytiva, provides helpful insig…

Article Oligonucleotide Development and Manufacturing Workflow
Click here to view >> Learn more on key considerations when setting up an oligonucleotide workflow with this infographic.

Article Successful Development of Scalable AAV Processes: Part 2 of 2
Watch the Q&A interview >> In the second of a two-part series, Anki Magnusson, Staff Research Engineer, Protein and Viral Production, and Åsa Hagner-McWhirter, PhD, Senior Scientist, Bio…

Article Increasing mRNA Capabilities and Capacity for Growing Market Needs
Click here to read more >> The success of the mRNA vaccine market is fueling high demand for mRNA, resulting in a critical need to address the manufacturing bottlenecks.

Article Key Process Considerations for Therapeutic Oligonucleotides
Click here to read the article >> Learn more about scalable solutions for developing and manufacturing oligonucleotide therapeutics.

Article Novavax Reports on Two Vaccine Efficacy Studies
Novavax’s COVID-19 vaccine is 90.4% effective and maintains efficacy when administered with an influenza vaccine. Novavax announced on June 14, 2021, results from two studies of is recombinant…

Article Cytiva and Pall Corporation Investing 1.5 Billion USD Over Two Years to Meet Growing Demand for Biotechnology Solutions
Click here to read more >> An ongoing strategic growth plan from Cytiva and Pall Corporation, part of the Danaher (NYSE: DHR) Corporation, will expand manufacturing capacity and services acros…

Show All Results

Previous PageNext Page